New Media Offers Cost-Efficient Ways to Reach and Engage Targets

Manhattan ResearchOver 145 million U.S. adults use the Internet to research health information, according to pharmaceutical and healthcare market research company Manhattan Research. The company has just released Cybercitizen Health v8.0, a multi-client study and strategic advisory service focused on how consumers use media and technology for health information and its impact on treatment and product decisions.

"Tough economic times cause marketers to be held more accountable for spending and measurement," said Mark Bard, Manhattan Research President, "With over 145 million consumers online for health, new media offers cost-effective ways to reach and engage target audiences. In order to efficiently allocate budgets, companies must understand the rapidly evolving health media channels and how consumers are using them to complement and replace the traditional offline health system."

Manhattan Research will host a webinar event, "Is TV Dead? How the New New Media Changes Pharmaceutical DTC Advertising," on October 14th at 11am EST and October 16th at 3pm EST. The webinar will help pharmaceutical and healthcare marketers understand the optimal media mix in the face of an uncertain economy. Meredith Abreu Ressi, VP of Research, will overview key market data and trends from CybercitizenÒ Health v8.0. Register here: https://manhattanresearch.webex.com.

Webinar Topics:

  • Evolving Consumer Use of TV and Video

How can marketers play the consumer shift to online video for entertainment and information to their advantage?

  • Going Mobile for Health

What are the latest trends and strategies for reaching a growing market of consumers using their mobile phones to find health info?

  • Engaging in Health 2.0

How are patients and caregivers using online communities, widgets, blogs, and wikis, and what should companies and agencies be doing about it? This topic is especially relevant for marketers looking to reach those most active in health social media, like cancer and fibromyalgia patients.

  • The Online Health Shake Up

What will the recent Waterfront Media-Revolution Health merger mean for pharma companies and their media partners? How can marketers stay ahead of the curve? Will sites eventually serve as a conduit linking physicians with their patients?

  • The Doctor…err…the Internet will See You Now

How does the decrease in consumer reliance on the physician affect your brand?

About Cybercitizen® Health v8.0
Cybercitizen® Health was fielded in Q3 2008 among 8,714 U.S. adults (ages 18+). In addition to the data, clients receive strategic deliverables including research reports, client briefings, and access to the Manhattan Research analyst team to answer specific questions. For topics and available therapeutic segmentations (80+), visit http://www.manhattanresearch.com/cch.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...